全球阵发性睡眠性血红蛋白尿药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

全球阵发性睡眠性血红蛋白尿药物市场需求预计将从 2022 年的 57.1 亿美元增至 2030 年的近 147.4 亿美元，2023-2030 年研究期间CAGR为 12.6%。

阵发性睡眠性血红蛋白尿 (PNH) 药物是专门用于治疗和控制阵发性夜间血红蛋白尿（一种罕见且可能危及生命的血液疾病）的药物。其特征是红血球异常分解，导致尿液中出现血红素、血栓，并增加贫血、疲劳和器官损伤等併发症的风险。

市场动态

PNH 的罕见性及其被归类为罕见疾病导致医疗需求未被满足，从而鼓励了该领域的研究和开发。生物製药的进步，特别是像依库珠单抗 (Soliris) 这样的单株抗体，改变了 PNH 的治疗。由于 PNH 药物的罕见性，其被指定为孤儿药，这为製药公司提供了诱因。意识和诊断能力的提高导致更多的 PNH 诊断，从而增加了对有效药物的需求。全球人口老化，PNH 在成年人中更为普遍，进一步放大了市场潜力。策略合作和伙伴关係加速了药物开发，而医疗保健基础设施和报销政策则影响患者的取得。正在进行的临床试验和研究计划透过探索新的治疗选择来促进市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球阵发性睡眠性血红素尿症药物市场的各个细分市场进行了包容性评估。阵发性睡眠性血红蛋白尿药物产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的阵发性睡眠性血红蛋白尿药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。阵发性睡眠性血红素尿症药物市场的主要参与者包括Alexion Pharmaceuticals、Takeda Pharmaceutical Company Limited (Shire Plc)、Akari Therapeutics、Apellis Pharmaceuticals、Ra Pharmaceuticals、Achillion Pharmaceuticals、Amgen Inc.、Regeneron Pharmaceuticals, Inc.、Fceuticals, Inc.、Fceutical . Hoffmann-La罗氏公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：阵发性睡眠性血红素尿药 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按处理方式进行的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球阵发性睡眠性血红素尿药市场分析：依治疗分类

• 按治疗概述
• 历史和预测数据
• 按治疗分析
• 药物
• 干细胞移植
• 输血

第 6 章：全球阵发性夜间血红蛋白尿药物市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 7 章：阵发性睡眠性血红素尿药公司的竞争格局

• 阵发性睡眠性血红素尿药市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 8 章：公司简介

• 公司股份分析
• 市场集中度
• Alexion Pharmaceuticals
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Takeda Pharmaceutical Company Limited (Shire Plc)
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Akari Therapeutics
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Apellis Pharmaceuticals
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Ra Pharmaceuticals
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Achillion Pharmaceuticals
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Amgen Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Regeneron Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• F. Hoffmann-La Roche AG.
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Paroxysmal Nocturnal Hemoglobinuria Drug Market is presumed to reach the market size of nearly USD 14.74 BN by 2030 from USD 5.71 BN in 2022 with a CAGR of 12.6% under the study period 2023 - 2030.

Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs are medications designed to treat and manage Paroxysmal Nocturnal Hemoglobinuria, a rare and potentially life-threatening blood disorder. It is characterized by the abnormal breakdown of red blood cells, leading to hemoglobin in the urine, blood clots, and an increased risk of complications such as anemia, fatigue, and organ damage.

MARKET DYNAMICS

The rarity of PNH and its classification as a rare disease contribute to an unmet medical need, encouraging research and development in the field. Advances in biopharmaceuticals, particularly monoclonal antibodies like eculizumab (Soliris), have transformed PNH treatment. Orphan drug designation for PNH drugs, driven by the condition's rarity, provides incentives for pharmaceutical companies. Increased awareness and diagnostic capabilities lead to more PNH diagnoses, boosting the demand for effective drugs. The global aging population, with PNH more prevalent in adults, further amplifies market potential. Strategic collaborations and partnerships accelerate drug development, while healthcare infrastructure and reimbursement policies influence patient access. Ongoing clinical trials and research initiatives contribute to market growth by exploring new therapeutic options.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of paroxysmal nocturnal hemoglobinuria drug. The growth and trends of paroxysmal nocturnal hemoglobinuria drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the paroxysmal nocturnal hemoglobinuria drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

• Medication
• Stem Cell Transplant
• Blood Transfusion

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Paroxysmal Nocturnal Hemoglobinuria Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Paroxysmal Nocturnal Hemoglobinuria Drug market include Alexion Pharmaceuticals, Takeda Pharmaceutical Company Limited (Shire Plc), Akari Therapeutics, Apellis Pharmaceuticals, Ra Pharmaceuticals, Achillion Pharmaceuticals, Amgen Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET ANALYSIS BY TREATMENT

• 5.1 Overview by Treatment
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Treatment
• 5.4 Medication Historic and Forecast Sales by Regions
• 5.5 Stem Cell Transplant Historic and Forecast Sales by Regions
• 5.6 Blood Transfusion Historic and Forecast Sales by Regions

6 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2. North America By Segment Sales Analysis
  • 6.3.3. North America By Country Sales Analysis
  • 6.3.4. United State Sales Analysis
  • 6.3.5. Canada Sales Analysis
  • 6.3.6. Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2. Europe by Segment Sales Analysis
  • 6.4.3. Europe by Country Sales Analysis
  • 6.4.4. United Kingdom Sales Analysis
  • 6.4.5. France Sales Analysis
  • 6.4.6. Germany Sales Analysis
  • 6.4.7. Italy Sales Analysis
  • 6.4.8. Russia Sales Analysis
  • 6.4.9. Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2. Asia Pacific by Segment Sales Analysis
  • 6.5.3. Asia Pacific by Country Sales Analysis
  • 6.5.4. China Sales Analysis
  • 6.5.5. India Sales Analysis
  • 6.5.6. Japan Sales Analysis
  • 6.5.7. South Korea Sales Analysis
  • 6.5.8. Australia Sales Analysis
  • 6.5.9. South East Asia Sales Analysis
  • 6.5.10. Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2. Latin America by Segment Sales Analysis
  • 6.6.3. Latin America by Country Sales Analysis
  • 6.6.4. Brazil Sales Analysis
  • 6.6.5. Argentina Sales Analysis
  • 6.6.6. Peru Sales Analysis
  • 6.6.7. Chile Sales Analysis
  • 6.6.8. Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2. Middle East & Africa by Segment Sales Analysis
  • 6.7.3. Middle East & Africa by Country Sales Analysis
  • 6.7.4. Saudi Arabia Sales Analysis
  • 6.7.5. UAE Sales Analysis
  • 6.7.6. Israel Sales Analysis
  • 6.7.7. South Africa Sales Analysis
  • 6.7.8. Rest Of Middle East And Africa Sales Analysis

7 . COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG COMPANIES

• 7.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8 . COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG INDUSTRY

• 8.1. Company Share Analysis
• 8.2. Market Concentration Rate
• 8.3. Alexion Pharmaceuticals
  • 8.3.1. Company Overview
  • 8.3.2. Company Revenue
  • 8.3.3. Products
  • 8.3.4. Recent Developments
• 8.4. Takeda Pharmaceutical Company Limited (Shire Plc)
  • 8.4.1. Company Overview
  • 8.4.2. Company Revenue
  • 8.4.3. Products
  • 8.4.4. Recent Developments
• 8.5. Akari Therapeutics
  • 8.5.1. Company Overview
  • 8.5.2. Company Revenue
  • 8.5.3. Products
  • 8.5.4. Recent Developments
• 8.6. Apellis Pharmaceuticals
  • 8.6.1. Company Overview
  • 8.6.2. Company Revenue
  • 8.6.3. Products
  • 8.6.4. Recent Developments
• 8.7. Ra Pharmaceuticals
  • 8.7.1. Company Overview
  • 8.7.2. Company Revenue
  • 8.7.3. Products
  • 8.7.4. Recent Developments
• 8.8. Achillion Pharmaceuticals
  • 8.8.1. Company Overview
  • 8.8.2. Company Revenue
  • 8.8.3. Products
  • 8.8.4. Recent Developments
• 8.9. Amgen Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Revenue
  • 8.9.3. Products
  • 8.9.4. Recent Developments
• 8.10. Regeneron Pharmaceuticals Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Revenue
  • 8.10.3. Products
  • 8.10.4. Recent Developments
• 8.11. F. Hoffmann-La Roche AG.
  • 8.11.1. Company Overview
  • 8.11.2. Company Revenue
  • 8.11.3. Products
  • 8.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Treatment (USD MN)
• Medication Market Sales by Geography (USD MN)
• Stem Cell Transplant Market Sales by Geography (USD MN)
• Blood Transfusion Market Sales by Geography (USD MN)
• Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Paroxysmal Nocturnal Hemoglobinuria Drug Report
• Market Research Process
• Market Research Methodology
• Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Treatment
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis By Treatment (USD MN)
• Medication Market Sales by Geography (USD MN)
• Stem Cell Transplant Market Sales by Geography (USD MN)
• Blood Transfusion Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.